IP Gateway is emerging as a leading firm in Queensland, Australia, for patent matters in the life sciences. Dr Alison McMillan who has over 25 year’s patent experience in the life sciences field, leads the IP Gateway Life Science group which includes Dr Jack King-Scott, Dr Timothy Fitzgerald and Dr Christy Grobbler.
In recent years, the IP Gateway life sciences group has grown to include these four operators with research PhDs. The group has substantial experience with drafting, prosecution, and oppositions across a range of technologies, including pharmaceuticals, diagnostics, medical devices, genomics and molecular biology, agribiotech, biochemistry, and chemical engineering.
The members of the team have scientific training across a broad range of scientific disciplines and have combined and complimentary patent experience across the fields of molecular biology, immunology, pharmaceuticals, protein chemistry, biotechnology DNA technology, microbiology, vaccines, assay/diagnostics development, medical devices and treatment, and biomaterials science.
IP Gateway is acutely aware of the effort involved in developing IP in the life sciences space, and is committed to achieving the best possible outcome for clients and associates. In both Australia and New Zealand, there are idiosyncrasies associated with the prosecution of therapeutic claims, and biotechnology more generally. The Group’s Life Science experience is not limited to Australia and New Zealand and extends to overseas and in particular major jurisdictions such as Europe and the USA. The group is confident that associates will recognise the benefits of having cases handled by operators providing genuine expertise and outstanding attention to detail.
This diverse technical specialty and breadth of experience allows the Life Sciences Group to work with and provide clients with comprehensive and high level advice and service grounded in a fundamental understanding of the core science.